Castle Biosciences CSTL Increase (Decrease) In Operating Lease, Right-Of-Use Assets
Increase (Decrease) In Operating Lease, Right-Of-Use Assets at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept cstl:IncreaseDecreaseInOperatingLeaseRightOfUseAssets.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's increase (decrease) in operating lease, right-of-use assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's increase (decrease) in operating lease, right-of-use assets?
- Castle Biosciences (CSTL) reported increase (decrease) in operating lease, right-of-use assets of -$371K in Q1 2026.
- How has Castle Biosciences's increase (decrease) in operating lease, right-of-use assets changed year-over-year?
- Castle Biosciences's increase (decrease) in operating lease, right-of-use assets increased by 11.7% year-over-year, from -$420K to -$371K.
- What is the long-term trend for Castle Biosciences's increase (decrease) in operating lease, right-of-use assets?
- Over 3 years (2021 to 2025), Castle Biosciences's increase (decrease) in operating lease, right-of-use assets has grown at a 13.8% compound annual growth rate (CAGR), from -$931K to -$1.37M.
- What does increase (decrease) in operating lease, right-of-use assets mean?
- This reflects the net change in the carrying value of right-of-use assets associated with operating leases during the reporting period. It captures the impact of new lease agreements, modifications, or impairments on the company's balance sheet. Monitoring this helps analysts understand the company's commitment to long-term physical infrastructure and its impact on operating cash flow.